<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03566238</url>
  </required_header>
  <id_info>
    <org_study_id>A4250-005</org_study_id>
    <nct_id>NCT03566238</nct_id>
  </id_info>
  <brief_title>This Study Will Investigate the Efficacy and Safety of A4250 in Children With PFIC 1 or 2</brief_title>
  <acronym>PEDFIC 1</acronym>
  <official_title>A Double-Blind, Randomized, Placebo-Controlled, Phase 3 Study to Demonstrate Efficacy and Safety of A4250 in Children With Progressive Familial Intrahepatic Cholestasis Types 1 and 2 (PEDFIC 1)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Albireo</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Albireo</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Double blind, randomized, placebo controlled, Phase 3 study to investigate the efficacy and
      safety of low doses and high doses of A4250 compared to placebo in children with PFIC
      (deficiencies of familial intrahepatic cholestasis-1 or bile salt export pump).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Up to 50 sites in the following countries will take part in this study:

      Australia, Belgium, Canada, France, Germany, Israel, Italy, Netherlands, Poland, Spain,
      Sweden, Turkey, United Kingdom, United States, and Saudi Arabia
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 16, 2018</start_date>
  <completion_date type="Anticipated">July 2020</completion_date>
  <primary_completion_date type="Anticipated">July 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Double-Blind, Randomized, Placebo-Controlled</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in pruritus (US)</measure>
    <time_frame>From baseline over the last 5 months of the treatment period</time_frame>
    <description>Change in pruritus as indexed by caregiver-reported (Albireo ObsRO instrument) observed scratching compared to placebo</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Bile acid reduction (EU and rest of world)</measure>
    <time_frame>From baseline to Week 24</time_frame>
    <description>Bile acid responder rate on treatment compared to the placebo group</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bile acid reduction (US)</measure>
    <time_frame>From baseline to Week 24</time_frame>
    <description>Bile acid responder rate on treatment compared to the placebo group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in pruritus (EU and rest of world)</measure>
    <time_frame>From baseline over the last 5 months of the treatment period</time_frame>
    <description>Change in pruritus as indexed by caregiver-reported (Albireo ObsRO instrument) observed scratching compared to placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fasting serum bile acids (s-BA)</measure>
    <time_frame>From baseline to Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in serum ALT concentration</measure>
    <time_frame>From baseline to Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in growth</measure>
    <time_frame>From baseline to Week 24</time_frame>
    <description>defined as the linear deficit (weight for age and body mass index) compared to the standard growth curves (Z-score, standard deviation from P50)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients achieving meaningful reduction in caregiver-reported observed scratching</measure>
    <time_frame>From baseline over the last 5 months of the treatment period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in sleep disturbances</measure>
    <time_frame>From baseline over the last 5 months of the treatment period</time_frame>
    <description>measured with the Albireo PRO instrument</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in sleep disturbances, including number of awakenings</measure>
    <time_frame>From baseline over the last 5 months of the treatment period</time_frame>
    <description>measured with the ObsRO instrument</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in patient-reported itch severity</measure>
    <time_frame>From baseline over the last 5 months of the treatment period</time_frame>
    <description>measured by the average daily score of the Albireo PRO instrument</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients undergoing biliary diversion surgery or liver transplantation</measure>
    <time_frame>From randomization to week 24</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">62</enrollment>
  <condition>PFIC1</condition>
  <condition>PFIC2</condition>
  <arm_group>
    <arm_group_label>A4250 low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Capsules for oral administration (40 ug/kg) once daily for 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A4250 high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Capsules for oral administration (120 ug/kg) once daily for 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Capsules for oral administration (to match active) once daily for 24 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>A4250 (odevixibat)</intervention_name>
    <description>A4250 is a small molecule and selective inhibitor of IBAT.</description>
    <arm_group_label>A4250 high dose</arm_group_label>
    <arm_group_label>A4250 low dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo identical in appearance to active drug (A4250)</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  A male or female patient with a clinical diagnosis of PFIC Type 1 or 2 and with a body
             weight above 5 kg

          -  Patient must have clinical genetic confirmation of PFIC-1 or PFIC-2

          -  Patient must have elevated s-BA concentration

          -  Patient must have history of significant pruritus and a caregiver reported observed
             scratching in the eDiary

          -  Patient and/or legal guardian must sign informed consent (and assent) as appropriate.

          -  Patients will be expected to have a consistent caregiver(s) for the duration of the
             study

          -  Caregivers and age-appropriate patients (≥8 years of age) must be willing and able to
             use an eDiary device as required by the study

        Key Exclusion Criteria:

          -  Patient with pathologic variations of the ABCB11 gene that predict complete absence of
             the BSEP protein

          -  Patient with past medical history or ongoing presence of other types of liver disease
             including, but not limited to, the following:

               1. Biliary atresia of any kind

               2. Benign recurrent intrahepatic cholestasis, indicated by any history of normal s
                  BAs

               3. Suspected or proven liver cancer or metastasis to the liver on imaging studies

               4. Histopathology on liver biopsy that is suggestive of alternate non-PFIC related
                  etiology of cholestasis

          -  Patient with past medical history or ongoing chronic diarrhea

          -  Any patient with suspected or confirmed cancers except for basal cell carcinoma

          -  Patient with a past medical history of chronic kidney disease with an impaired renal
             function and a glomerular filtration rate &lt;70 mL/min/1.73 m^2

          -  Patient with surgical history of disruption of the enterohepatic circulation (biliary
             diversion surgery) within 6 months prior to start of Screening Period

          -  Patient has had a liver transplant or a liver transplant is planned within 6 months of
             randomization

          -  Decompensated liver disease

          -  Patient suffers from uncontrolled, recalcitrant pruritic condition other than PFIC

          -  Patient who has been previously treated with an IBAT inhibitor whose pruritus has not
             responded to treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Children's Hospital Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Colorado</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University School of Medicine</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30329</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins School of Medicine</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center - Presbyterian Hospital Building</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine - Texas Children's Liver Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Royal Children's Hospital</name>
      <address>
        <city>Melbourne</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cliniques Universitaires Saint-Luc</name>
      <address>
        <city>Woluwe-Saint-Lambert</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Hospital for Sick Children</name>
      <address>
        <city>Toronto</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>British Columbia Children's Hospital</name>
      <address>
        <city>Vancouver</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University and Pediatric Hospital of Lyon</name>
      <address>
        <city>Bron</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universite Paris SUD - Hopitaux Universitaires Paris-Sud - Hopital Bicetre</name>
      <address>
        <city>le Kremlin Bicetre</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de la Timone</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Necker-Enfants maladies</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uniklinikum Essen- Kinderklinik II</name>
      <address>
        <city>Essen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover</name>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kinderklinik Tübingen, Universitätsklinikum Tübingen</name>
      <address>
        <city>Tubingen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rambam Medical Centre</name>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shaare-Zedek Mc</name>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Schneider Children's Medical Center Of Israel</name>
      <address>
        <city>Petach-Tikva</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Papa Giovanni XXIII</name>
      <address>
        <city>Bergamo</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Of Padova</name>
      <address>
        <city>Padova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Regina Margherita</name>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Center Groningen</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitair Medisch Centrum (UMC) Utrecht</name>
      <address>
        <city>Utrecht</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instytut Pomnik - Centrum Zdrowia Dziecka</name>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>King Faisal Specialist Hospital &amp; Research Centre</name>
      <address>
        <city>Riyadh</city>
        <zip>11211</zip>
        <country>Saudi Arabia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Astrid Lindgren Children's Hospital, Karolinska University Hospital</name>
      <address>
        <city>Solna</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gazi University</name>
      <address>
        <city>Ankara</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hacettepe University Faculty of Medicine</name>
      <address>
        <city>Ankara</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Akdeniz University</name>
      <address>
        <city>Antalya</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istanbul University Medical Faculty</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inonu University Medical Faculty</name>
      <address>
        <city>Malatya</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Birmingham Women's and Children's NHS Foundation Trust</name>
      <address>
        <city>Birmingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leeds General Infirmary</name>
      <address>
        <city>Leeds</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Liver Studies - Kings College Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Saudi Arabia</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>May 25, 2018</study_first_submitted>
  <study_first_submitted_qc>June 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 25, 2018</study_first_posted>
  <last_update_submitted>March 4, 2020</last_update_submitted>
  <last_update_submitted_qc>March 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pediatric</keyword>
  <keyword>Cholestasis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholestasis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

